Cardiomyopathy News

 
 
  • No Benefit of Levothyroxine in Heart Donors New data challenge the common practice of levothyroxine administration in potential heart donors after brain death to preserve heart function and make more hearts available for transplantation.
  • TCT 2023 Transapical Valve Replacement Relieves Mitral Regurgitation Transapical mitral valve replacement by catheter eliminated mitral regurgitation and improved hemodynamics in a frail high-risk population, results of the SUMMIT trial show.
  • ACR 2023 Conditional Recommendations Rule in New SARD ILD Guidelines In spring 2024, the ACR is expected to release guidelines to help inform the screening, monitoring, and treatment of interstitial lung disease (ILD) in people with SARDs.
  • AHA 2023 Sudden Cardiac Deaths Down Among NCAA Athletes The incidence of sudden cardiac deaths has decreased over the past two decades among NCAA collegiate athletes but remains relatively high for male basketball players and certain other groups.
  • AHA 2023 'Smart' Stethoscope Spots Peripartum Cardiomyopathy Screening with an AI-enhanced digital stethoscope doubled the diagnoses of life-threatening peripartum cardiomyopathy in Nigeria, where the incidence is the highest in the world.
  • ACR 2023 Pregnancy in Rheumatic Disease Quadruples CVE Risk Pregnant patients with lupus and concomitant APS had an 18-fold higher risk for a cardiovascular event during and up to 6 weeks postpartum than did pregnant individuals without these conditions.
  • Excellent Outcome of Ross Procedure After Two Decades Survival in patients who underwent the Ross procedure, a technically complex technique to replace the aortic valve, is 83% after 25 years, which matches that of the general population.
  • AHA 2023 Women Have Worse Outcomes in Cardiogenic Shock A new analysis of a large contemporary registry of patients with cardiogenic shock has shown worse outcomes for women than men, driven particularly by those with shock related to heart failure.
  • AANEM 2023 DMD Gene Therapy Safe, Effective at 4 Years Four years after a single dose of SRP-9001 gene therapy, four children with Duchenne muscular dystrophy show sustained stabilization of motor function that would otherwise show expected decline.
  • Second Pig Heart Recipient Dies Laurence Faucette lived for 6 weeks after the transplant of a genetically modified pig heart and did well until a few days before his death.
  • Cytokinetics Exploring Options After Receiving Takeover Interest Heart diseases-focused drug developer Cytokinetics is weighing options after receiving takeover interest.
  • TCT 2023 Trilogy TAVR Safe, Effective in Aortic Regurgitation The Trilogy transcatheter aortic valve replacement system was safe and effective for high-risk surgical patients with aortic regurgitation, improving LV remodeling and function, in the ALIGN-AR trial.
  • SMFM 2023 A Dozen Genes Found Dangerous in Pregnancy Conditions linked to the 12 genes included cardiomyopathy, hemorrhage, gestational hypertensive disorders and more.
  • COVID Coronary Plaque Infection Confirms CV Risk Evidence showing the SARS-CoV-2 virus directly infects coronary atherosclerotic plaques, causing a persistent inflammatory response, may lead to new approaches for managing patients after infection.
  • Durable LVAD for Advanced HF Still Underutilized Durable mechanical circulatory support is an important treatment option for patients with advanced heart failure, but remains underutilized, a new JACC scientific statement concludes.
  • HFSA 2023 Hopeful Insights, No Overall HFpEF Gains From Splanchnic Nerve Ablation: REBALANCE-HF An otherwise negative trial may have identified a subgroup of patients likely to respond well to this potential transcatheter therapy for heart failure.
  • Alert FDA Denies Approval for Patisiran in ATTR Cardiomyopathy In a complete response letter, the FDA said the clinical meaningfulness of patisiran's effects in cardiomyopathy of ATTR amyloidosis are not established, despite good reviews from an advisory panel.
  • HFSA 2023 Semaglutide Win in HFpEF With Obesity Regardless of LVEF Were the GLP-1 receptor agonist drug's apparent benefits in STEP-HFpEF due solely to weight loss or additional mechanisms? The trial offers a clue, experts say.
  • More Data Support Heart Donation After Circulatory Death Mortality and other outcomes after heart transplantation are comparable for patients receiving organs donated after circulatory death or after brain death.
  • Second Pig-Heart Transplant Patient at UM Faring Well He should be well served by lessons from last year's turbulent case of David Bennett, the first patient at the University of Maryland to receive a genetically modified porcine heart.